Argenx announces validation of european marketing authorization application for efgartigimod in generalized myasthenia gravis

Breda, the netherlands – august 2 5 , 2021 – argenx (euronext & nasdaq: argx), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it has submitted, and the european medicines agency (ema) has validated, the marketing authorization application (maa) for the company's investigational fcrn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis (gmg). validation of the maa confirms that the application is sufficiently complete to begin the formal review process.
ARGX Ratings Summary
ARGX Quant Ranking